FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 39 filers reported holding FATE THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $12,000 | -14.3% | 4,596 | 0.0% | 0.00% | – |
| Q3 2016 | $14,000 | +100.0% | 4,596 | +6.2% | 0.00% | – |
| Q2 2016 | $7,000 | -12.5% | 4,327 | 0.0% | 0.00% | – |
| Q1 2016 | $8,000 | -46.7% | 4,327 | 0.0% | 0.00% | – |
| Q4 2015 | $15,000 | -34.8% | 4,327 | 0.0% | 0.00% | – |
| Q3 2015 | $23,000 | -11.5% | 4,327 | +5.9% | 0.00% | – |
| Q2 2015 | $26,000 | +136.4% | 4,085 | +87.5% | 0.00% | – |
| Q1 2015 | $11,000 | 0.0% | 2,179 | -3.1% | 0.00% | – |
| Q4 2014 | $11,000 | 0.0% | 2,248 | 0.0% | 0.00% | – |
| Q3 2014 | $11,000 | -15.4% | 2,248 | +8.4% | 0.00% | – |
| Q2 2014 | $13,000 | – | 2,073 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |